MBio Diagnostics is developing a portfolio of innovative tests for remote settings where lab-quality results are vital in making time-critical decisions on-the-spot.
The LightDeck® platform was designed as a no compromises solution to on-the-spot diagnostics.
- Quality: Highly sensitive tests that deliver lab-quality results
- Quick + Quantitative: Actionable results in as little as 5 minute with more data to inform treatment decisions
- Multiplex: Multiple tests per sample plus internal quality control to maximize confidence in results and improved patient experience
The LightDeck COVID-19 Total Antibody Test is to determine past SARS-CoV-2 infection.
Host-response biomarkers in acute infection can help stage patients and inform treatment decisions.
We are developing tests to assess heart attack: a high-sensitivity troponin test and a 3-plex Cardiac Panel.
MBio offers tests for toxins associated with harmful algae bloom.